Literature DB >> 15365683

Phenotypic assessment of galanin overexpressing and galanin receptor R1 knockout mice in the tail suspension test for depression-related behavior.

Andrew Holmes1, Qian Li, Elizabeth A Koenig, Eric Gold, Dejaimenay Stephenson, Rebecca J Yang, Jennifer Dreiling, Tim Sullivan, Jacqueline N Crawley.   

Abstract

RATIONALE: Galanin and its receptors exert inhibitory neuromodulatory control over brain monoamines. Rat studies revealed that galanin expression is upregulated by exposure to stressors and that galanin manipulations modify neuroendocrine and behavioral responses to stress, leading to the hypothesis that galanin mediates depression-related behaviors.
METHODS: In the present study, we examined the role of galanin in modulating antidepressant-related behavior in galanin overexpressing transgenic (GAL-tg) mice and galanin receptor R1 knockout (GAL-R1 KO) mice, using the tail suspension test (TST). Quantitative autoradiography for 5-HT(1A)-R and serotonin transporter binding density tested for changes in these two major regulatory components of the 5-HT system in galanin mutant mice.
RESULTS: Baseline TST behavior was normal in GAL-tg and GAL-R1 KO mice, and intracerebroventricular administration of galanin failed to alter TST behavior in normal C57BL/6J mice. The TST anti-immobility effects of acute treatment with the serotonin reuptake inhibitor, fluoxetine (0-30 mg/kg), and the norepinephrine reuptake inhibitor, desipramine (0-30 mg/kg), were unaltered in galanin mutant mice. Hippocampal 5-HT(1A)-R density was significantly elevated in GAL-tg and GAL-R1 KO mice, while hippocampal 5-HTT density was reduced in GAL-R1 KO mice, relative to controls.
CONCLUSION: Neither pharmacological nor molecular genetic manipulations of galanin altered depression-related profiles in the TST. Possible functional alterations in hippocampal 5-HT neurotransmission may have contributed to these negative results. These preliminary findings provide evidence against the hypothesis that galanin plays a central role in mouse depression-related behaviors. It remains possible that galanin modulates depression-related responses in other experimental paradigms and species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365683     DOI: 10.1007/s00213-004-1997-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  Anxiogenic-like action of galanin after intra-amygdala administration in the rat.

Authors:  C Möller; W Sommer; A Thorsell; M Heilig
Journal:  Neuropsychopharmacology       Date:  1999-10       Impact factor: 7.853

2.  Enhanced hippocampal noradrenaline and serotonin release in galanin-overexpressing mice after repeated forced swimming test.

Authors:  Takashi Yoshitake; Fu-Hua Wang; Eugenia Kuteeva; Kristina Holmberg; Masatoshi Yamaguchi; Jacqueline N Crawley; Robert Steiner; Tamas Bartfai; Sven Ove Ogren; Tomas Hökfelt; Jan Kehr
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-30       Impact factor: 11.205

3.  Intraventricular galanin modulates a 5-HT1A receptor-mediated behavioural response in the rat.

Authors:  I Misane; H Razani; F H Wang; A Jansson; K Fuxe; S O Ogren
Journal:  Eur J Neurosci       Date:  1998-04       Impact factor: 3.386

4.  Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult.

Authors:  Cornelius Gross; Xiaoxi Zhuang; Kimberly Stark; Sylvie Ramboz; Ronald Oosting; Lynn Kirby; Luca Santarelli; Sheryl Beck; René Hen
Journal:  Nature       Date:  2002-03-28       Impact factor: 49.962

5.  Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors.

Authors:  Z Q Xu; T J Shi; T Hökfelt
Journal:  J Comp Neurol       Date:  1998-03-09       Impact factor: 3.215

6.  Differential galanin receptor-1 and galanin expression by 5-HT neurons in dorsal raphé nucleus of rat and mouse: evidence for species-dependent modulation of serotonin transmission.

Authors:  Jari A Larm; Pei-Juan Shen; Andrew L Gundlach
Journal:  Eur J Neurosci       Date:  2003-02       Impact factor: 3.386

Review 7.  Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies.

Authors:  J N Crawley; J K Belknap; A Collins; J C Crabbe; W Frankel; N Henderson; R J Hitzemann; S C Maxson; L L Miner; A J Silva; J M Wehner; A Wynshaw-Boris; R Paylor
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

Review 8.  Galanin overexpressing transgenic mice.

Authors:  Jacqueline N Crawley; Elliott J Mufson; John G Hohmann; Dawit Teklemichael; Robert A Steiner; Kristina Holmberg; Zhi-Qing D Xu; Karin Hygge Blakeman; Xiao-Jun Xu; Zsuzsanna Wiesenfeld-Hallin; Tamas Bartfai; Tomas Hökfelt
Journal:  Neuropeptides       Date:  2002 Apr-Jun       Impact factor: 3.286

Review 9.  In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.

Authors:  J F Cryan; C Mombereau
Journal:  Mol Psychiatry       Date:  2004-04       Impact factor: 15.992

10.  Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus.

Authors:  S Consolo; G Baldi; G Russi; G Civenni; T Bartfai; A Vezzani
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

View more
  15 in total

1.  Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm.

Authors:  C Kiselycznyk; P Svenningsson; E Delpire; A Holmes
Journal:  Neuroscience       Date:  2011-06-23       Impact factor: 3.590

Review 2.  Galanin and its receptors in neurological disorders.

Authors:  Linda Lundström; Anna Elmquist; Tamas Bartfai; Ulo Langel
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 3.  Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.

Authors:  Sven Ove Ogren; Eugenia Kuteeva; Tomas Hökfelt; Jan Kehr
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray.

Authors:  Peng Wang; Hui Li; Swapnali Barde; Ming-Dong Zhang; Jing Sun; Tong Wang; Pan Zhang; Hanjiang Luo; Yongjun Wang; Yutao Yang; Chuanyue Wang; Per Svenningsson; Elvar Theodorsson; Tomas G M Hökfelt; Zhi-Qing David Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

5.  Increased fear- and stress-related anxiety-like behavior in mice lacking tuberoinfundibular peptide of 39 residues.

Authors:  D B Fegley; A Holmes; T Riordan; C A Faber; J R Weiss; S Ma; S Batkai; P Pacher; A Dobolyi; A Murphy; M W Sleeman; T B Usdin
Journal:  Genes Brain Behav       Date:  2008-09-17       Impact factor: 3.449

Review 6.  The TIP39-PTH2 receptor system: unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms.

Authors:  Arpád Dobolyi; Miklós Palkovits; Ted B Usdin
Journal:  Prog Neurobiol       Date:  2009-10-24       Impact factor: 11.685

Review 7.  Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.

Authors:  Konstantinos A Paschos; Stavroula Veletza; Ekaterini Chatzaki
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

Review 8.  Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.

Authors:  David Weinshenker; Philip V Holmes
Journal:  Brain Res       Date:  2015-11-20       Impact factor: 3.252

9.  Galanin mediates features of neural and behavioral stress resilience afforded by exercise.

Authors:  N R Sciolino; J M Smith; A M Stranahan; K G Freeman; G L Edwards; D Weinshenker; P V Holmes
Journal:  Neuropharmacology       Date:  2014-10-06       Impact factor: 5.250

10.  Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests.

Authors:  Xiaoying Lu; Brendon Ross; Manuel Sanchez-Alavez; Eric P Zorrilla; Tamas Bartfai
Journal:  Neuropeptides       Date:  2008-06-12       Impact factor: 3.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.